Target Price | $610.05 |
Price | $402.36 |
Potential | 51.62% |
Number of Estimates | 19 |
19 Analysts have issued a price target Synopsys 2026 . The average Synopsys target price is $610.05. This is 51.62% higher than the current stock price. The highest price target is $685.00 70.25% , the lowest is $520.00 29.24% . | |
A rating was issued by 23 analysts: 21 Analysts recommend Synopsys to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Synopsys stock has an average upside potential 2026 of 51.62% . Most analysts recommend the Synopsys stock at Purchase. |
19 Analysts have issued a sales forecast Synopsys 2025 . The average Synopsys sales estimate is $6.8b . This is 11.63% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $6.8b 12.39% , the lowest is $6.7b 10.36% .
This results in the following potential growth metrics:
2024 | $6.1b | 14.95% |
---|---|---|
2025 | $6.8b | 10.58% |
2026 | $7.6b | 12.57% |
2027 | $8.7b | 13.61% |
2028 | $9.8b | 12.75% |
10 Analysts have issued an Synopsys EBITDA forecast 2025. The average Synopsys EBITDA estimate is $2.9b . This is 74.12% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $2.9b 76.70% , the lowest is $2.9b 72.26% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $1.9b | 12.12% |
---|---|---|
2025 | $2.9b | 50.63% |
2026 | $3.3b | 15.12% |
2027 | $3.9b | 16.41% |
2028 | $4.4b | 14.92% |
2024 | 31.31% | 2.46% |
---|---|---|
2025 | 42.65% | 36.22% |
2026 | 43.61% | 2.25% |
2027 | 44.68% | 2.45% |
2028 | 45.54% | 1.92% |
11 Synopsys Analysts have issued a net profit forecast 2025. The average Synopsys net profit estimate is $1.6b . This is 23.32% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $1.7b 18.82% , the lowest is $1.6b 24.56% .
This results in the following potential growth metrics and future Net Margins:
2024 | $2.2b | 83.21% |
---|---|---|
2025 | $1.6b | 28.55% |
2026 | $1.9b | 16.76% |
2027 | $2.3b | 24.54% |
2028 | $2.8b | 19.14% |
2024 | 36.63% | 59.38% |
---|---|---|
2025 | 23.67% | 35.39% |
2026 | 24.55% | 3.72% |
2027 | 26.91% | 9.61% |
2028 | 28.44% | 5.69% |
11 Analysts have issued a Synopsys forecast for earnings per share. The average Synopsys EPS is $10.37 . This is 23.30% lower than earnings per share in the financial year 2024. The highest EPS forecast is $10.98 18.79% , the lowest is $10.20 24.56% .
This results in the following potential growth metrics and future valuations:
2024 | $14.51 | 83.21% |
---|---|---|
2025 | $10.37 | 28.53% |
2026 | $12.10 | 16.68% |
2027 | $15.07 | 24.55% |
2028 | $17.96 | 19.18% |
Current | 30.56 | 50.20% |
---|---|---|
2025 | 39.87 | 30.46% |
2026 | 34.15 | 14.35% |
2027 | 27.42 | 19.71% |
2028 | 23.01 | 16.08% |
Based on analysts' sales estimates for 2025, the Synopsys stock is valued at an EV/Sales of 8.97 and an P/S ratio of 9.44 .
This results in the following potential growth metrics and future valuations:
Current | 10.02 | 27.13% |
---|---|---|
2025 | 8.97 | 10.46% |
2026 | 7.97 | 11.17% |
2027 | 7.02 | 11.98% |
2028 | 6.22 | 11.31% |
Current | 10.53 | 23.90% |
---|---|---|
2025 | 9.44 | 10.42% |
2026 | 8.38 | 11.17% |
2027 | 7.38 | 11.98% |
2028 | 6.54 | 11.31% |
Analyst | Rating | Action | Date |
---|---|---|---|
B of A Securities |
Buy
➜
Buy
|
Unchanged | Apr 16 2025 |
Mizuho |
Outperform
➜
Outperform
|
Unchanged | Apr 15 2025 |
Keybanc |
Overweight
➜
Overweight
|
Unchanged | Apr 15 2025 |
Wells Fargo |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Feb 27 2025 |
Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Feb 27 2025 |
Needham |
Buy
➜
Buy
|
Unchanged | Feb 27 2025 |
Rosenblatt |
Buy
➜
Buy
|
Unchanged | Feb 25 2025 |
Analyst Rating | Date |
---|---|
Unchanged
B of A Securities:
Buy
➜
Buy
|
Apr 16 2025 |
Unchanged
Mizuho:
Outperform
➜
Outperform
|
Apr 15 2025 |
Unchanged
Keybanc:
Overweight
➜
Overweight
|
Apr 15 2025 |
Unchanged
Wells Fargo:
Equal-Weight
➜
Equal-Weight
|
Feb 27 2025 |
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Feb 27 2025 |
Unchanged
Needham:
Buy
➜
Buy
|
Feb 27 2025 |
Unchanged
Rosenblatt:
Buy
➜
Buy
|
Feb 25 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.